Dasatinib, which shows robust efficacy in mouse model of TBI by directly impinging on the pathway activated by KCNB1 oxidation and in the APP/PS1 mouse model of AD, had only modest effects in preventing the AD-like pathology of the 3xTg-AD mouse7,18. This evidence concerns the gene KCNB1 and Alzheimer disease.